Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH to Significantly Reduce the use of Chimpanzees in Research

Published: Friday, June 28, 2013
Last Updated: Friday, June 28, 2013
Bookmark and Share
NIH plans to retain but not breed up to 50 chimpanzees for future biomedical research.

The National Institutes of Health plans to substantially reduce the use of chimpanzees in NIH-funded biomedical research and designate for retirement most of the chimpanzees it currently owns or supports. NIH Director Francis S. Collins, M.D., Ph.D. accepted most of the recommendations made by an independent advisory council for implementing a set of principles and criteria defined by the Institute of Medicine for the use of chimpanzees in NIH-funded research.

The chimpanzees that will remain available for research will be selected based on research projects that meet the IOM’s principles and criteria for NIH funding. The chimpanzees designated for retirement could eventually join more than 150 other chimpanzees already in the Federal Sanctuary System. The Federal Sanctuary System was established in 2002 by the Chimpanzee Health Improvement, Maintenance and Protection (CHIMP) Act   and Chimp Haven operates the Federal Sanctuary System, which is overseen by NIH.

“Americans have benefitted greatly from the chimpanzees’ service to biomedical research, but new scientific methods and technologies have rendered their use in research largely unnecessary,” said Dr. Collins. “Their likeness to humans has made them uniquely valuable for certain types of research, but also demands greater justification for their use. After extensive consideration with the expert guidance of many, I am confident that greatly reducing their use in biomedical research is scientifically sound and the right thing to do.”

In accepting the recommendations, NIH plans to:

• retain but not breed a small fraction of chimpanzees for future research that meets the IOM principles and criteria

• provide ethologically appropriate facilities (i.e., as would occur in their natural environment) for those chimpanzees as defined by NIH based on the advisory council recommendations and with space requirements yet to be determined

• establish a review panel to consider research projects proposing the use of chimpanzees with the IOM principles and criteria after projects have cleared the NIH peer review process

• wind down research projects using NIH-owned or -supported chimpanzees that do not meet the IOM principles and criteria in a way that preserves the research and minimizes the impact on the animals

• retire the majority of the NIH-owned chimpanzees deemed unnecessary for biomedical research to the Federal Sanctuary System contingent upon resources and space availability in the sanctuary system

Some technical changes in NIH’s legal authority are needed to retire additional chimpanzees to the Federal Sanctuary System. NIH will continue working with Congress to remedy a provision that currently limits the amount of financial resources NIH may put toward retiring chimpanzees and caring for them in the Federal Sanctuary System.

While broadly accepting the recommendations of ethologically appropriate facilities, NIH did not accept, due to the lack of scientific consensus, the recommendation that the primary living space of research chimpanzees be at least 1,000 square feet per chimpanzee. NIH will engage chimpanzee behavior and facilities experts to determine the appropriate minimum space requirement for research chimpanzees.

“Today’s decision by NIH culminates more than two years of intensive deliberations among NIH leadership, independent chimpanzee experts, researchers, bioethicists, and members of the public,” said James M. Anderson, M.D., Ph.D., NIH deputy director for program coordination, planning, and strategic initiatives, whose division oversees the NIH Chimpanzee Management Program. “We are grateful to all who have contributed their insight and expertise during the advisory process.”

NIH’s full response to the recommendations and public comments can be found here

The events that led to the decision by NIH are:

• In December 2010, the NIH Director commissioned a study by the Institute of Medicine to determine the continued scientific need for chimpanzees in NIH-funded research  .

• The IOM, in its recommendations in December 2011, concluded that most current use of chimpanzees in biomedical research is unnecessary and that the use of chimpanzees in research that may still be needed should be guided by a set of principles and criteria.

• That same month, Dr. Collins accepted the IOM recommendations. He charged a working group of the Council of Councils (CoC), an independent advisory committee, to make recommendations on how NIH should implement the IOM principles and criteria.

• The CoC presented its recommendations(PDF - 695KB) in January 2013.

• The CoC recommendations were issued for public comment in the same month.

The U.S. Fish and Wildlife Service (USFWS) recently issued a proposed rule (PDF - 695KB)   that lists captive chimpanzees as endangered. NIH expects to adapt its policies for research projects using chimpanzees to comply with the conservation guidelines that the USFWS establishes in a potential final rule.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Thursday, May 05, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Friday, November 13, 2015
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Tuesday, November 10, 2015
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Tuesday, October 06, 2015
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Wednesday, September 30, 2015
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Tuesday, September 29, 2015
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Friday, June 26, 2015
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Monday, November 10, 2014
NIH Launches 3 Integrated Precision Medicine Trials
Findings to answer questions about addition of targeted therapies in earlier stage disease and help understand the prevalence and natural history of these genomic changes in earlier stage lung cancer.
Wednesday, August 20, 2014
Study Finds Gut Microorganisms May Determine Cancer Treatment Outcome
An intact population of microorganisms that derive food and benefit from other organisms living in the intestine is required for optimal response to cancer therapy.
Monday, November 25, 2013
NIH Scientists Pursue New Therapies to Improve Rare Disease Drug Development
Projects selected for potential to treat specific rare diseases.
Friday, September 13, 2013
Improving Gene Therapy for Eye Diseases
Researchers developed a less invasive technique that delivers genes across the retinas of mouse and monkey eyes.
Friday, July 05, 2013
NIH Funds Development of Tissue Chips to Help Predict Drug Safety
DARPA and FDA to collaborate on therapeutic development initiative.
Wednesday, July 25, 2012
Blockade of Learning and Memory Genes may Occur Early in Alzheimer's Disease
A repression of gene activity in the brain appears to be an early event affecting people with Alzheimer's disease. In mouse models of Alzheimer's disease, this epigenetic blockade and its effects on memory were treatable.
Thursday, March 01, 2012
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Growing Stem Cells More Safely
Nurturing stem cells atop a bed of mouse cells works well, but is a non-starter for transplants to patients – Brown University scientists are developing a synthetic bed instead.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!